Skip to main content

Table 6 All-cause mortality rate per 100,000 person-years by gender

From: Baseline incidence of meningitis, malaria, mortality and other health outcomes in infants and young sub-Saharan African children prior to the introduction of the RTS,S/AS01E malaria vaccine

  Kombewa, Kenya Kintampo, Ghana Navrongo, Ghana Overall
n PY Value (95% CI) n PY Value (95% CI) n PY Value (95% CI) n PY Value (95% CI)
Female N = 1018 N = 1786 N = 584 N = 3388
All causes 7 600 1166 (469, 2402) 12 1154 1040 (537, 1817) 1 374 267 (7, 1488) 20 2129 940 (574, 1451)
AESI 0 600 0 (0, 614) 0 1154 0 (0, 320) 0 374 0 (0, 985) 0 2129 0 (0, 173)
Meningitis 0 600 0 (0, 614) 0 1154 0 (0, 320) 0 374 0 (0, 985) 0 2129 0 (0, 173)
Malaria 0 600 0 (0, 614) 6 1154 520 (191, 1132) 0 374 0 (0, 985) 6 2129 282 (103, 614)
P. falciparum 0 600 0 (0, 614) 1 1154 87 (2, 483) 0 374 0 (0, 985) 1 2129 47 (1, 262)
Other AEs 7 600 1166 (469, 2402) 6 1154 520 (191, 1132) 1 374 267 (7, 1488) 14 2129 658 (360, 1104)
Male N = 1093 N = 1817 N = 599 N = 3509
All causes 14 649 2157 (1179, 3620) 7 1176 595 (239, 1227) 1 379 264 (7, 1469) 22 2204 998 (626, 1511)
AESI 0 649 0 (0, 568) 0 1176 0 (0, 314) 0 379 0 (0, 973) 0 2204 0 (0, 167)
Meningitis 0 649 0 (0, 568) 0 1176 0 (0, 314) 0 379 0 (0, 973) 0 2204 0 (0, 167)
Malaria 3 649 462 (95, 1351) 1 1176 85 (2, 474) 0 379 0 (0, 973) 4 2204 182 (49, 465)
P. falciparum 2 649 308 (37, 1113) 1 1176 85 (2, 474) 0 379 0 (0, 973) 3 2204 136 (28, 398)
Other AEs 11 649 1695 (846, 3033) 6 1176 510 (187, 1111) 1 379 264 (7, 1469) 18 2204 817 (484, 1291)
Total N = 2111 N = 3603 N = 1183 N = 6897
All causes 21 1249 1681 (1041, 2569) 19 2330 816 (491, 1274) 2 754 265 (32, 959) 42 4332 969 (699, 1310)
AESI 0 1249 0 (0, 295) 0 2330 0 (0, 158) 0 754 0 (0, 490) 0 4332 0 (0, 85)
Meningitis 0 1249 0 (0, 295) 0 2330 0 (0, 158) 0 754 0 (0, 490) 0 4332 0 (0, 85)
Malaria 3 1249 240 (50, 702) 7 2330 300 (121, 619) 0 754 0 (0, 490) 10 4332 231 (111, 424)
P. falciparum 2 1249 160 (19, 578) 2 2330 86 (10, 310) 0 754 0 (0, 490) 4 4332 92 (25, 236)
Other AEs 18 1249 1441 (854, 2277) 12 2330 515 (266, 900) 2 754 265 (32, 959) 32 4332 739 (505, 1043)
  1. According-to-protocol cohort, 5 to 17 months age-group N, Number of study participants at risk during a follow-up period of approximately 6 months after each dose of the virtual primary vaccination schedule censored at the next dose; n, number of cases reported during that follow-up period
  2. CI: confidence interval; PY: person-years; AE: adverse event; AESI: adverse event of special interest